Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy.
- Creators
- Noel, Georges
- Huchet, Aymeri
- Feuvret, Loic
- Maire, Jean Philippe
- Verrelle, Pierre
- Le Rhun, Emilie
- Aumont, Maud
- Thillays, François
- Sunyach, Marie Pierre
- Henzen, Chantal
- Missohou, Fernand
- de Crevoisier, Renaud
- Bondiau, Pierre Yves
- Collin, Philippe
- Durando, Xavier
- Truc, Gilles
- Kerr, Christine
- Bernier, Valérie
- Clavier, Jean-Baptiste
- Atlani, David
- d'Hombres, Anne
- Vinchon-Petit, Sandrine
- Lagrange, Jean Léon
- Taillandier, Luc
- Others:
- Centre Paul Strauss ; CRLCC Paul Strauss
- CHU Bordeaux [Bordeaux]
- Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP) ; UNICANCER
- Centre René Gauducheau ; CRLCC René Gauducheau
- Centre Léon Bérard [Lyon]
- CRLCC Eugène Marquis (CRLCC)
- Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL) ; UNICANCER-Université Côte d'Azur (UCA)
- Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL) ; UNICANCER
- Centre Alexis Vautrin (CAV)
- Centre Paul Papin ; CRLCC Paul Papin
- CIC - CHU Henri Mondor ; Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
- Service de Neuro-Oncologie [CHRU Nancy] ; Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)
Description
Purpose of this study was to determine the effect of waiting time for radiotherapy on overall survival of patients with glioblastoma treated in the EORTC-NCIC trial at 18 centers in France. A total of 400 adult patients with glioblastoma who were treated between January 1, 2006 and December 31, 2006 were included. There were 282 patients with "minimum criteria" according to the EORTC-NCIC trial: (i) concurrent chemotherapy with temozolomide; and (ii) age between 18 and 70 years old. Among these patients, 229 were treated with adjuvant temozolomide and were classified as "maximal criteria". One-hundred and eighteen patients were in the "without minimal criteria" group. Waiting time from the first symptom (FS-RT), pathology diagnosis (P-RT), multidisciplinary meeting (MM-RT), surgery (S-RT), and CT scan for delineation (CT-RT) until the start of radiotherapy were recorded. Median follow-up for all patients was 327 days. Overall, median FS-RT, P-RT, MM-RT, CT-RT, and S-RT times were 77, 36, 32, 12, and 41 days, respectively. Median, and 12 and 24-month overall survival were 409 days, and 56.3 ± 2.1 % and 27.6 ± 2.6 %, respectively. Univariate analysis failed to reveal a difference in survival, irrespective of the delay. In multivariate analysis, independent favorable prognostic factors for overall survival were age (p ≤ 0.0001) and type of surgery (p = 0.0006). In this large series treated during the EORTC-NCIC protocol period, waiting time until radiotherapy did not seem to affect patient outcome.
Abstract
International audience
Additional details
- URL
- https://hal.archives-ouvertes.fr/hal-00905430
- URN
- urn:oai:HAL:hal-00905430v1
- Origin repository
- UNICA